Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Mark A. Dawson"'
Autor:
Paola Grandi, Mark A. Dawson, Lital Estrella Weil, Thilo Werner, Barak Rotblat, Panagis Filippakopoulos, Vered Chalifa-Caspi, Michal Feldman, Khawla Alasad, Dan Levy, Sarah Picaud, Ruth A. McAdam, Margarita Kublanovsky, Rab K. Prinjha, Trevor D. Chapman, Elina Abaev-Schneiderman, Huw D. Lewis, Zlata Vershinin, Marcus Bantscheff, Enid Y.N. Lam, Menachem Y. Sklarz
Publikováno v:
Science Advances
Lysine methylation of BRD4 selectively determines the recruitment of E2F1 to specific target genes to regulate mRNA translation.
The transcriptional coactivator BRD4 has a fundamental role in transcription regulation and thus became a promising
The transcriptional coactivator BRD4 has a fundamental role in transcription regulation and thus became a promising
Publikováno v:
Blood. 134(22)
A hallmark of acute myeloid leukemia (AML) is epigenetic dysregulation, which is initiated by recurrent translocations and/or mutations in transcription factors and chromatin regulators. This manifests as a block in myeloid differentiation and an inc
Autor:
Kevin Tran, Tatiana Cañeque, Giovanna Pomilio, Kristin K. Brown, Yih-Chih Chan, Andrew G. Cox, Kate McArthur, Veronique Litalien, Sebastian Müller, Estelle Duprez, Mark A. Dawson, Sylvain Garciaz, Brian Liddicoat, Georg Ramm, Kah-Lok Chan, Raphaël Rodriguez, Marian L. Burr, Enid Y.N. Lam, Laura MacPherson, Fiona C. Brown, Sarah-Jane Dawson, Andrew A Guirguis, David C.S. Huang, Mathilde Poplineau, Andrew H. Wei
Publikováno v:
Blood. 138:267-267
Although the BCL2 inhibitor venetoclax have been transformative in the management of AML, therapeutic resistance and relapse are frequently observed. In light of the urgent need to uncover novel therapeutic options in AML, we sought to study the pote
Autor:
Alexandra L. Garnham, Peter E. Czabotar, Andrew F. Wilks, Stefan P Glaser, Peter Hall, Scott Taylor, Mark A. Dawson, John Thomas Feutrill, Zhen Xu, Carl R. Walkley, Phillip P. Sharp, Kate E. Jarman, Tamas Hatfaludi, Helene Jousset, David J. Segal, Christopher J. Burns, Jean-Marc Garnier, David C.S. Huang, Dean Tyler, Anthony Nicholas Cuzzupe
Publikováno v:
ACS Medicinal Chemistry Letters. 8:1298-1303
A number of diazepines are known to inhibit bromo- and extra-terminal domain (BET) proteins. Their BET inhibitory activity derives from the fusion of an acetyl-lysine mimetic heterocycle onto the diazepine framework. Herein we describe a straightforw
Autor:
Omer Gilan, Colin M. House, Joseph A. Trapani, Ilia Voskoboinik, Ruby H. P. Law, Imran G House, James C. Whisstock, Mark A. Dawson, Amelia Jean Brennan
Publikováno v:
EMBO reports. 18:1775-1785
Perforin is a highly cytotoxic pore‐forming protein essential for immune surveillance by cytotoxic lymphocytes. Prior to delivery to target cells by exocytosis, perforin is stored in acidic secretory granules where it remains functionally inert. Ho
Autor:
Ravikiran Vedururu, Mark A. Dawson, Ken Doig, Sarah-Jane Dawson, Stephen Q. Wong, Paul Yeh, Michael Dickinson, Sarah Ftouni, Piers Blombery, Devbarna Sinha, David Westerman, Rishu Agarwal, Tane Hunter, Chun Yew Fong
Publikováno v:
Blood. 129:1685-1690
The diagnosis and monitoring of myelodysplastic syndromes (MDSs) are highly reliant on bone marrow morphology, which is associated with substantial interobserver variability. Although azacitidine is the mainstay of treatment in MDS, only half of all
Autor:
Margaret A. Goodell, Yun Huang, Mark A. Dawson, Jia Li, Clifford Stephan, Anna Guzman, Lei Guo, Deqiang Sun, Peter J.A. Davies, Yubin Zhou, Tingting Li, Minjung Lee, Hongxiang Zeng
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-16 (2020)
Nature Communications
Nature Communications
Primary and acquired drug resistance imposes a major threat to achieving optimized clinical outcomes during cancer treatment. Aberrant changes in epigenetic modifications are closely involved in drug resistance of tumor cells. Using BET inhibitor (BE
Autor:
Sarah-Jane Dawson, Constantine S. Tam, Rishu Agarwal, Rodney J. Hicks, Mary Ann Anderson, Mark A. Dawson, Mathias Bressel, David Westerman, David Ritchie, Sasanka M. Handunnetti, Kate Burbury, Andrew W. Roberts, Rachel Koldej, Stephen Lade, John F. Seymour, Juliana Di Iulio, Besiat Birbirsa
Publikováno v:
Blood. 134:756-756
Background: The phase II AIM trial (Tam et al, NEJM 2018; NCT02471391), using combination BTK inhibitor ibrutinib (IB) and BCL-2 inhibitor venetoclax (VEN) therapy achieved excellent 16 week complete remission rates (CRR) (primary endpoint; 62%) in p
Autor:
Joy Liu, Omer Gilan, Marnie E. Blewitt, Ian J. Majewski, Alicia Oshlack, Mark A. Dawson, Sarah Kinkel, Darcy Moore, Andrew Keniry, Christoffer Flensburg, Linden J. Gearing, Roman Galeev, Jonas Larsson, Kelsey Breslin, Warren S. Alexander, Stanley Chun-Wei Lee, Kelan Chen
Publikováno v:
Blood. 125:1890-1900
Polycomb repressive complex 2 (PRC2) plays a key role in hematopoietic stem and progenitor cell (HSPC) function. Analyses of mouse mutants harboring deletions of core components have implicated PRC2 in fine-tuning multiple pathways that instruct HSPC
Autor:
Michael Dickinson, Adrian Alegre, Brian J. P. Huntly, Carlos Fernández de Larrea, Jeffrey Botbyl, James Winnberg, Manali Kamdar, Paolo Gallipoli, Alejandro Martín, Won Seog Kim, Natalie Karpinich, Maria-Victoria Mateos, Thierry Horner, Raul Cordoba, Aristeidis Chaidos, Faisal Basheer, Brandon E. Kremer, Jin Seok Kim, Lijoy K. Mathew, Anastasios Karadimitris, Mark A. Dawson, Arindam Dhar, Paul Yeh
Publikováno v:
Blood. 132:1682-1682
BACKGROUND: Patients with relapsed and/or refractory non-Hodgkin's lymphoma (NHL), especially those with aggressive lymphomas, have overall poor prognosis. Novel targets and therapies are under investigation. Molibresib (GSK525762) is a potent and sp